02186 LUYE PHARMA
- 2.950
- +0.020+0.68%
LUYE PHARMA News
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Citi Upgrades Luye Pharma to Buy From Sell; Price Target Is HK$4
Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
luye pharma (02186) released its interim results, with a shareholder's profit of 0.388 billion yuan, an increase of 158.6% year-on-year.
Luye Pharma (02186) released its financial results for the six months ended June 30, 2024, during which the group achieved revenue...
Luye Pharma Group Reports Strong Mid-Year Financials
Express News | Luye Pharma Group H1 Revenue RMB 3,074.6 Million
Express News | Luye Pharma Group H1 Gross Profit RMB 2,078.6 Million
Express News | Luye Pharma Group H1 Net Income RMB 438.2 Million
Express News | Luye Pharma Group H1 Gross Margin 67.6%
LUYE PHARMA: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 JUNE 2024
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Luye Pharma Sets Date for Financial Results Review
Luye Pharma (02186.HK) is planning to hold a board of directors meeting on August 28 to approve its mid-year performance.
Luye Pharma (02186.HK) announced on August 15th that the board of directors will hold a meeting on Wednesday, August 28th, 2024 to approve the interim performance of the company and its subsidiaries for the six months ending June 30, 2024, and to consider the distribution of interim dividends (if any).
LUYE PHARMA: NOTICE OF BOARD MEETING
Luye Pharma Group's Subsidiary's Investor Buys 25% Stake in Nanjing Luye for 1 Billion Yuan
Luye Pharma Group Completes Key Investment Phase
Luye Pharma (02186.HK): A third party has preliminarily completed the investment in Shenzhen Luye.
LuYe Pharma (02186.HK) announced that it has invested in a third-party, Shenzhen LuYe. The board of directors announced that the preconditions for the initial investment have been met, and the initial investment was completed on August 12, 2024. After completing the initial investment, Nanjing LuYe is owned by the group and investors with 75% and 25% respectively. The investor has nominated a director to the board of directors of Nanjing LuYe.
Analysis
Price Target
No Data
No Data